

A meta-analysis of heart rate variability in major depression

Celine Koch¹, Marcel Wilhelm¹, Stefan Salzmann¹, Winfried Rief¹
and Frank Euteneuer^{2,1}

¹Clinical Psychology and Psychotherapy, Philipps Universität, Marburg, Germany and ²Clinical Psychology and Psychotherapy, Medical School Berlin, Berlin, Germany

Review Article

Cite this article: Koch C, Wilhelm M, Salzmann S, Rief W, Euteneuer F (2019). A meta-analysis of heart rate variability in major depression. *Psychological Medicine* 1–10. <https://doi.org/10.1017/S0033291719001351>

Received: 27 December 2018

Revised: 16 May 2019

Accepted: 21 May 2019

Key words:

Cardiovascular; depression; heart rate variability

Author for correspondence:

Frank Euteneuer, E-mail: frank.euteneuer@medschool-berlin.de

Abstract

Background. Major depression (MD) is a risk factor for cardiovascular disease. Reduced heart rate variability (HRV) has been observed in MD. Given the predictive value of HRV for cardiovascular health, reduced HRV might be one physiological factor that mediates this association.

Methods. The purpose of this study was to provide up-to-date random-effects meta-analyses of studies which compare resting-state measures of HRV between unmedicated adults with MD and controls. Database search considered English and German literature to July 2018.

Results. A total of 21 studies including 2250 patients and 1982 controls were extracted. Significant differences between patients and controls were found for (i) frequency domains such as HF-HRV [Hedges' $g = -0.318$; 95% CI (-0.388 to -0.247)], LF-HRV (Hedges' $g = -0.195$; 95% CI (-0.332 to -0.059)), LF/HF-HRV (Hedges' $g = 0.195$; 95% CI (0.086 – 0.303)) and VLF-HRV (Hedges' $g = -0.096$; 95% CI (-0.179 to -0.013)), and for (ii) time-domains such as IBI (Hedges' $g = -0.163$; 95% CI (-0.304 to -0.022)), RMSSD (Hedges' $g = -0.462$; 95% CI (-0.612 to -0.312)) and SDNN (Hedges' $g = -0.266$; 95% CI (-0.431 to -0.100)).

Conclusions. Our findings demonstrate that all HRV-measures were lower in MD than in healthy controls and thus strengthens evidence for lower HRV as a potential cardiovascular risk factor in these patients.

Introduction

Depression has a lifetime prevalence of 19% in industrialized nations and affects approximately 322 million people worldwide (World Health Organization, 2008, 2017). In middle- and high-income countries, depression and cardiovascular disease (CVD) are the leading causes for impairments in quality of life and CVD is also a primary cause for mortality (Wittchen *et al.*, 2010; Christopher and Murray, 2016).

Depression and CVD are interrelated (Shaffer *et al.*, 2012). For example, meta-analyses of longitudinal prospective studies strengthen the assumption that depressive symptoms are an independent risk factor for the development of CVDs, such as hypertension (Meng *et al.*, 2012), myocardial infarction (van der Kooy *et al.*, 2007; Gan *et al.*, 2014; Wu and Kling, 2016) and coronary heart disease (Rugulies, 2002; Nicholson *et al.*, 2006a, 2006b; van der Kooy *et al.*, 2007; Gan *et al.*, 2014; Wu and Kling, 2016). In addition, depressive symptoms are frequently observed in patients with CVD: in survivors of acute myocardial infarction, major depression (MD) was prevalent in nearly 20% shortly after the acute medical event (Thombs *et al.*, 2014). Clinically relevant depressive symptoms occur in around one-third of patients after stroke (Hackett and Pickles, 2014). Depressive symptoms are also predictive for morbidity and mortality in coronary heart disease (Goldston and Baillie, 2008).

Heart rate variability (HRV) refers to variations between two successive heartbeats which ensures optimal adaption to environmental challenges. HRV is influenced by parasympathetic autonomic activation including the vagus nerve (which slows down heart rate) and via sympathetic activation (which accelerates heart rate). HRV is frequently quantified using time-domain measures such as the standard deviation of NN intervals (SDNN) and the root mean square of successive differences between normal heartbeats (RMSSD), which is more influenced by vagal activity than SDNN. HRV is also often described in terms of frequency-domain measures. High-frequency (HF)-HRV primarily reflects parasympathetic vagal activity. Low-frequency (LF)-HRV is more complex and may include both sympathetic and parasympathetic influences. Very-low-frequency (VLF)-HRV might reflect long-term regulation mechanisms (e.g. thermoregulation or hormonal factors). A third category of HRV is respiratory sinus arrhythmia (RSA), which reflects heart rate variations via the vagus nerve related to the respiratory cycle (Task Force of The European Society of Cardiology and The North American & Society of Pacing and Electrophysiology, 1996; Shaffer *et al.*, 2014; Shaffer and Ginsberg, 2017).

Chronically reduced HRV indicates an autonomic imbalance. A substantial body of research suggests that reductions in HRV predict poor cardiovascular health outcomes in both populations without baseline CVD and clinical samples (Buccelletti *et al.*, 2009; Hillebrand *et al.*, 2013; Kubota *et al.*, 2017). Previous meta-analyses suggest that HRV is lower in patients with MD than in healthy controls across all age groups (Kemp *et al.*, 2010; Rottenberg, 2007; Koenig *et al.*, 2016; Brown *et al.*, 2018). Importantly, reduced HRV is not a specific feature of MD but rather a transdiagnostic factor which relates to several stress-related states, conditions and behavioral factors, as well as to several medical conditions and medications (Gidron *et al.*, 2018). Nevertheless, HRV might be an important mediator between depression and CVD (Sgoifo *et al.*, 2015; Shaffer and Ginsberg, 2017).

The latest meta-analysis investigating HRV in MD in (apart from late-life depression, see Brown *et al.*, 2018) was conducted by Kemp and colleagues in 2010 and included 11 studies (published until July 2009) (Kemp *et al.*, 2010). Results indicated that several HRV measures are lower in MD compared to controls by medium to large effect sizes. In the last decade, many studies have investigated HRV in MD. While some of them have also reported reductions in HRV (e.g. Berger *et al.*, 2011; Berger *et al.*, 2012; Kemp *et al.*, 2012; Brunoni *et al.*, 2013; Kemp and Quintana, 2013) others did not find significant differences or have attributed alterations in HRV to antidepressant treatment (Licht *et al.*, 2008; O'Regan *et al.*, 2015).

The purpose of this study is to provide up-to-date random-effects meta-analyses of studies that compare resting-state measures of HRV between unmedicated adults with MD (as defined by DSM-III-R, DSM-IV, DSM-IV-TR or DSM-5) and controls. Effects of antidepressants on HRV have been the subject of controversy and HRV alterations in MD may result in part from antidepressants, in particular tricyclic antidepressants (Kemp *et al.*, 2010, 2011, 2016; Licht *et al.*, 2011; Huang *et al.*, 2016). To avoid confounded or overestimated results, we therefore exclusively focus on studies that include participants without antidepressants, and also without cardiac drugs and CVD. Different from an earlier meta-analysis in this field, which has combined interrelated measures of HRV (Kemp *et al.*, 2010), our meta-analysis provides separate results for specific measures of HRV. This approach was facilitated by the increasing availability of HRV data from samples with MD and may enable a more differentiated understanding of HRV disturbances in MD. Further, the literature is inconclusive regarding equivalence and the approach of treating interrelated HRV measures equivalent, in particular when measures derived from short-term recordings (Task Force of The European Society of Cardiology and The North American & Society of Pacing and Electrophysiology, 1996; Berntson *et al.*, 2005; Kemp *et al.*, 2010; Shaffer and Ginsberg, 2017). Finally, this study considers appropriate methods to control for publication bias and investigates if ECG recording length and study quality moderate magnitudes of effect sizes.

Methods

Literature search and inclusion criteria

This meta-analysis was conducted according to the 'Preferred Reporting Items for Systematic Reviews and Meta-Analysis' (PRISMA) guidelines (Moher *et al.*, 2009). Online Supplement

1 includes the PRISMA-Checklist. Because this meta-analysis did not aim to compare intervention effects, it was not preregistered and no review protocol exists.

A systematic literature search was performed up to 10 July 2018. Two investigators (CK & FE) independently searched on PubMed and PsychINFO for publications using the terms [(depress*) AND (heart rate variability) OR HRV OR (cycle length variability) OR (RR variability) OR (heart period variability) OR vagal OR (autonomic nervous system) OR (ANS)]. Studies published since 1 January 1987 (the year of publication of DSM-III-R) were considered with no filters applied. Email alerts notified the investigators of potentially relevant studies published during the process of study selection. The ClinicalTrials.gov database was searched for unpublished studies. Disagreements between the investigators were solved by discussion. The search in PubMed and PsychINFO yielded 6121 and 1779 results, respectively. After removal of duplicates, 7104 titles and abstracts were screened. The search on ClinicalTrials.gov yielded 29 unpublished studies on depressive patients with HRV assessment. Reviews, meta-analyses, abstracts from conference proceedings and single-case studies were excluded. In particular, studies including patients with CVD, cardiac medication and antidepressants were excluded. Also, studies with samples of patients with diabetes and neurological disorders were excluded. Exclusion criteria for each study are outlined in online Supplement 2 (Table S1).

To be eligible for full-test screening, abstracts had to report a comparison of HRV in adults (≥ 18 years) in MD to healthy controls.

Studies were included if they:

- (1) reported a resting state time-or frequency domain measure of HRV in both (i) unmedicated adults with MD (as defined by DSM-III-R, DSM-IV, DSM-IV-TR or DSM-5) and (ii) age-matched healthy controls.
- (2) were published in a peer-reviewed journal
- (3) were written in English or German.

Data extraction

A data extraction sheet was developed based on inclusion criteria, previous meta-analyses (e.g. Tak *et al.*, 2009; Kemp *et al.*, 2010; Koenig *et al.*, 2016) and common study characteristics usually extracted in meta-analyses (e.g. year and country of publication). During the process of study extraction, the sheet was continually adapted. Information on the year and country of publication, matching, inclusion and exclusion criteria, sample size, mean age of participants, diagnostics (i.e. diagnosis assessment tool, medical and psychiatric comorbidities), as well as ECG recording length was extracted from all included studies. If data were not extractable (i.e. only provided in graphs), authors were contacted and asked for additional information. If the data could not be provided on time (Bär *et al.*, 2004; Chang *et al.*, 2015) a plot digitizer (Rohatgi, 2012, Web Plot Digitizer, available at <https://automeris.io/WebPlotDigitizer/>) was used to estimate the mean and standard deviation (s.d.). When standard errors were reported instead of standard deviations, the standard deviation was estimated in accordance to an earlier meta-analysis, by using the following formula: $SD = SE \times \sqrt{n}$ (Higgins and Green, 2011; Koenig *et al.*, 2016). Absolute values as well as logarithmically transformed values but not normalized values were included in the meta-analysis (Rottenberg, 2007; Tak *et al.*, 2009).





Fig. 1. PRISMA flow diagram.

Statistical analyses

The Comprehensive Meta-Analysis (CMA; Version 3) statistical software package (Borenstein *et al.*, 2014) was used to aggregate individual studies. Since sample sizes varied between studies and between samples with MD and controls within the same study, the adjusted mean difference (Hedges' g) was chosen as the primary summary measure and 95% confidence intervals were computed. Effect sizes of 0.2, 0.5 and 0.8 were considered as low, moderate and large effects (Cohen, 1988). Several study characteristics varied between studies (e.g. sample size, mean age and gender distribution). Therefore, non-random-variance in effect-sizes was assumed and random-effects models were chosen to compute the overall effect sizes for HRV-measures (Borenstein *et al.*, 2009). Heterogeneity was assessed using the I^2 index (Higgins and Thompson, 2002), which quantifies the amount of variation between studies that can be attributed to

true variation in effect sizes (e.g. an I^2 of 23% indicates that 23% of the variation in effect sizes between studies can be explained by true variation in effect sizes and not by sampling error). An I^2 of 25, 50 and 75% is considered as low, moderate and high heterogeneity, respectively. I^2 does not depend on the number of studies included in the meta-analysis or the metric of the effect size (Higgins *et al.*, 2003). To assess publication bias, funnel plots were visually inspected to discover possible asymmetry that might occur due to the selective publication of smaller studies reporting large effect sizes (Higgins and Green, 2008). Additionally, the trim and fill method was used as a statistical procedure as an estimate of the unbiased effect size (Duval and Tweedie, 2000). Meta-regression was performed on each of the HRV measures to test if the ECG recording length and study quality moderated the effect size. Two researchers (MW and SS) independently rated study quality using a slightly

Table 1. Random-effects meta-analysis forest plot for HF-HRV: Comparison between patients with Major Depression (MD) and healthy controls (HC).

modified rating scale adapted from Tak et al. (2009). Interrater reliability for independent ratings was in the range of almost perfect agreement ($\kappa = 0.823$). As the next step, any disagreements were resolved through discussion to obtain consistent values. Rating criteria and results are shown in online Supplement 4.

Results

The database search yielded 197 articles to be full-text screened. The gray literature search on ClinicalTrials.gov yielded no additional results since all potentially relevant studies were still recruiting. After full-text screening, 21 studies remained to be included in the meta-analysis, with $N = 2250$ patients and $N = 1982$ controls ($N = 4235$). Figure 1 illustrates results of the selection procedure. Characteristics of the included studies and HRV recording lengths for each study ($M = 10.68$ min, $S.D. = 9.66$ min, range = 28.33 min) are shown in online Supplementary Table S1. Separate meta-analyses were conducted for HRV frequency- and time-domains. We provide no meta-analysis for RSA, because only two studies were extracted, which differ in RSA calculation (Lehofer et al., 1997; Berger et al., 2012).

Meta-analysis 1 – frequency domain: high-frequency heart rate variability (HF-HRV)

Compared to control groups ($N = 1724$), depressed samples ($N = 1977$) showed a significant reduction in HF-HRV [$Z = -8.860$, $p < 0.001$; Hedges' $g = -0.318$; 95% CI (-0.388 to -0.247); $k = 13$, $N = 3701$], as illustrated in Table 1. There was no evidence for heterogeneity across studies ($\tau^2 = 0.00$, $\chi^2(13, N = 3701) = 12.513$, $p = 0.405$; $I^2 = 4.103\%$). The visual inspection of the funnel plot indicated slight asymmetry (online Supplement 3, Fig. S2). Using trim and fill did not change the effect size Hedges' $g = -0.318$; 95% CI (-0.388 to -0.247).

Meta-analysis 2 – frequency domain: low-frequency heart rate variability (LF-HRV)

Compared to control groups ($N = 1640$), depressed samples ($N = 1939$) showed a significant reduction in LF-HRV ($Z = -2.803$,

$p = 0.005$; Hedges' $g = -0.195$; 95% CI (-0.332 to -0.059); $k = 12$, $N = 3579$), as illustrated in Table 2. Heterogeneity across studies was low ($\tau^2 = 0.02$, $\chi^2(11, N = 3579) = 26.07$, $p = 0.009$; $I^2 = 26.12\%$). The visual inspection of the funnel plot indicated slight asymmetry (Supplement 3, Fig. S3). Using trim and fill attenuated the effect size to Hedges' $g = -0.158$; 95% CI (-0.297 to -0.019).

Meta-analysis 3 – frequency domain: very-low frequency heart-rate variability (VLF-HRV)



Compared to control groups ($N = 992$), depressed samples ($N = 1273$) showed a significant reduction in VLF-HRV [$Z = -2.263$, $p = 0.024$; Hedges' $g = -0.096$; 95% CI (-0.179 to -0.013); $k = 5$, $N = 2265$], as illustrated in Table 3. There was no evidence for heterogeneity across studies ($\tau^2 = 0.00$, $\chi^2(4, N = 2265) = 2.05$, $p = 0.726$; $I^2 = 0.00\%$). The visual inspection of the funnel plot indicated slight asymmetry (online Supplement 3, Fig. S4), but using trim and fill did not change the magnitude of the effect size.

Meta-analysis 4 – frequency domain: LF/HF ratio

Compared to control groups ($N = 2189$), depressed samples ($N = 1929$) exhibited a significantly higher LF/HF ratio ($Z = 3.525$, $p < 0.001$; Hedges' $g = 0.195$; 95% CI (0.086; 0.303); $k = 19$, $N = 4118$), as illustrated in Table 4. Heterogeneity across studies was low to moderate ($\tau^2 = 0.02$, $\chi^2(18, N = 4118) = 32.232$, $p = 0.021$; $I^2 = 44.16\%$). The visual inspection of the funnel plot indicated slight asymmetry (online Supplement 3, Fig. S5), but using trim and fill did not change the magnitude of the effect size.

Meta-analysis 5 – time domain: root mean square of successive differences between normal heartbeats (RMSSD)

Compared to control groups ($N = 337$), depressed samples ($N = 356$) showed a significant reduction in RMSSD [$Z = -6.037$, $p < 0.001$; Hedges' $g = -0.462$; 95% CI (-0.612 to -0.312); $k = 9$, $N = 692$], as illustrated in Table 5. There was no evidence for heterogeneity across studies [$\tau^2 = 0.00$, $\chi^2(8, N = 692) = 2.67$, $p = 0.954$;

Table 2. Random-effects meta-analysis forest plot for LF-HRV: Comparison between patients with Major Depression (MD) and healthy controls (HC).**Table 3.** Random-effects meta-analysis forest plot for VLF-HRV: Comparison between patients with Major Depression (MD) and healthy controls (HC).

$I^2 = 0.00\%$). The visual inspection of the funnel plot indicated slight asymmetry (online Supplement 3, Fig. S6). Using trim and fill changed the effect size to Hedges' $g = -0.480$; 95% CI (-0.623 to -0.339).

Meta-analysis 6 – time domain: standard deviation of the intervals between normal beats (SDNN)

Compared to control groups ($N = 271$), depressed samples ($N = 289$) presented a significant reduction of small effect size in SDNN [$Z = -3.142$, $p = 0.002$; Hedges' $g = -0.266$; 95% CI (-0.431 to -0.100); $k = 9$, $N = 560$], as illustrated in Table 6. There was no evidence for heterogeneity across studies [$\tau^2 = 0.00$, $\chi^2(5, N = 560) = 4.469$, $p = 0.484$; $I^2 = 0.00\%$]. The visual inspection of the funnel plot (online Supplement 3, Fig. S7) indicated no asymmetry and using trim and fill did not change the magnitude of the effect size.

Meta-analysis 7 – time domain: interbeat interval (IBI)

Compared to control groups ($N = 1855$), depressed samples ($N = 1535$) showed a significant reduction of small effect size in



IBI [$Z = -2.267$, $p = 0.023$; Hedges' $g = -0.163$; 95% CI (-0.304 to -0.022); $k = 7$, $N = 3390$], as illustrated in Table 7. Heterogeneity across studies was moderate [$\tau^2 = 0.02$, $\chi^2(6, N = 3390) = 16.629$, $p = 0.011$; $I^2 = 63.92\%$]. The visual inspection of the funnel plot indicated slight asymmetry (online Supplement 3, Fig. S8). Using trim and fill attenuated the effect size to Hedges' $g = -0.141$; 95% CI (-0.275 to -0.007).

Meta-regression 1 – impact of ECG recording length

Recording length did not moderate the differences between depressed samples and controls in HRV measures, except for the interbeat interval [$\beta = -0.0172$, 95% CI (-0.026 to -0.008)]. Here, greater recording length resulted in lower effect sizes. Results of the other meta-regressions are shown in online Supplement 5 (Table S2).

Meta-regression 2 – impact of study quality



Study quality did not moderate the differences between depressed samples and controls in any of the HRV measures. Results of meta-regressions are shown in online Supplement 6 (Table S3).

Table 4. Random-effects meta-analysis forest plot for LF/HF Ratio: Comparison between patients with Major Depression (MD) and healthy controls (HC).**Table 5.** Random-effects meta-analysis forest plot for RMSSD: Comparison between patients with Major Depression (MD) and healthy controls (HC).

Discussion

The purpose of this study was to provide up-to-date meta-analyses of studies that compare resting-state measures of HRV between unmedicated adults with MD and controls. Results suggest that patients with MD are likely to display small reductions in several measures of HRV such as HF-HRV, LF-HRV, SDNN and IBI and an increase in LF/HF ratio. The largest effect size was found for RMSSD, a time domain measure of HRV, suggesting that reductions in patients with MD in this measure are of small to moderate magnitude. The reduction in VLF-HRV was minimal but still statistically significant. Our

findings thus strengthen evidence that MD is not associated with alteration in specific indicators of HRV but rather with abnormalities in several time- and frequency-domain measures, although the effect sizes for these alterations differ. In this context, it is noteworthy that several time- and frequency-domain measures, rather than specific indicators, have predictive value for poor cardiovascular health outcomes in populations without known baseline CVD (Hillebrand et al., 2013). A further important feature of our meta-analyses is that we found no evidence for a moderating role of study quality. This negative finding strengthens robustness of the observed HRV alterations in MD.

Table 6. Random-effects meta-analysis forest plot for SDNN: Comparison between patients with Major Depression (MD) and healthy controls (HC).**Table 7.** Random-effects meta-analysis forest plot for IBI: Comparison between patients with Major Depression (MD) and healthy controls (HC).

Given the controversies about unfavorable effects of antidepressants on HRV (Kemp *et al.*, 2010, 2011, 2016; Licht *et al.*, 2010, 2011; Huang *et al.*, 2016), this meta-analysis with unmedicated samples clearly demonstrates that reductions in HRV are prevalent in depressed patients without antidepressants. However, effect sizes for differences in HRV measures between depressed patients and controls are substantially smaller than effects sizes for the reduction of HRV when starting the use of tricyclic or noradrenergic antidepressants (Licht *et al.*, 2010). These observations strengthen the assumption that HRV alterations in MD may be overestimated when studying patients who use antidepressants. In addition, although our findings result from cross-sectional analyses, the small to moderate effect sizes observed in this work may suggest that lower HRV does not completely explain the risk of CVD associated with MD. This is in line with previous research indicating that no single biological or behavioral factor accounts for more than a fraction of the total risk of CVD associated with depression (Carney and Freedland, 2017).

Our findings mostly support the results of a previous meta-analysis by Kemp *et al.* (2010), although these authors report a larger elevation in LF/HF ratio in MD than in our analysis. A further difference is that our study indicates a significant reduction in LF-HRV in MD while Kemp *et al.* (2010) found no evidence for differences in LF-HRV between patients and controls. Importantly, a recent meta-analysis focusing on late-life depression (Brown *et al.*, 2018) did not observe alterations in HF-HRV in MD but, consistent with our findings, a significant reduction in LF-HRV in MD (Brown *et al.*, 2018). Another recent

meta-analysis of HRV alterations in childhood and adolescent depression suggests that HF-HRV was lower in children with depression than in controls, but the authors did not analyze LF-HRV alterations (Koenig *et al.*, 2016). A possible reason why the present and previous meta-analyses (Kemp *et al.*, 2010; Koenig *et al.*, 2016) found differences in HF-HRV between MD and nondepressed controls while the meta-analysis including patients with late-life depression and older nondepressed participants did not (Brown *et al.*, 2018), may be because HF-HRV declines with aging (Jandackova *et al.*, 2016). Further reasons for partly differing results are speculative but it is important to note that our work considers a substantially larger number of patients with MD for analyses than previous publications. Our findings might thus provide more robust results.

Given the increased risk of patients with MD for CVD (Rugulies, 2002; Nicholson *et al.*, 2006a, 2006b; van der Kooy *et al.*, 2007; Meng *et al.*, 2012; Shaffer *et al.*, 2012; Gan *et al.*, 2014; Wu and Kling, 2016), reduced HRV has been considered an indicator of autonomic imbalance and one potential mediator in the relationship of depression and other stress-related states and conditions with poor health outcomes (Kop *et al.*, 2010; Kemp *et al.*, 2017). Reduced HRV and other indicators of autonomic dysfunction interact with peripheral inflammation, a further potential pathway between MD and CVD (Howren *et al.*, 2009; Dowlati *et al.*, 2010; Rief *et al.*, 2010; Haarala *et al.*, 2011; Euteneuer *et al.*, 2012; Jarczok *et al.*, 2014; Halaris, 2016). Reduced HRV is not a specific feature of depression but rather a transdiagnostic marker of health and well-being which can be

affected by several medical, psychosocial and behavioral factors (e.g. medical conditions, drugs, nutrition, smoking, physical activity) (Rozanski et al., 2005; Eller et al., 2011; Nemeroff and Goldschmidt-Clermont, 2012; Elderon and Whooley, 2013; Shaffer et al., 2014; Cohen et al., 2015; Pieritz et al., 2016; Kemp et al., 2017; Gidron et al., 2018; Young and Benton, 2018).

One important question in the context of HRV and depression is, whether interventions that aim to reduce depressive symptoms can also improve HRV in these patients. There is a large debate on whether antidepressants affect HRV. While tricyclic antidepressants seem to reduce HRV, findings for Serotonin Reuptake Inhibitors (SSRIs) or specific subgroups of SSRIs respectively are not clear or mainly result from cross-sectional studies which allow no causal assumptions (Kemp et al., 2010, 2016, 2011; Licht et al., 2011; Huang et al., 2016). The impact of psychological interventions on HRV in patients with MD without CVD is understudied and may be a promising aim for future studies. In an ongoing randomized controlled trial of our research group, we intend to address this issue by examining whether cognitive behavioral therapy, a standard treatment for depression, improve HRV in patients with MD (Euteneuer and Rief, 2016). Previous research indicates that cognitive behavioral therapy has beneficial effects on HRV in depressed patients with CVD and in older patients with manifest cardiovascular risk factors (Carney et al., 2005; Taylor et al., 2009). Moreover, a recent preliminary study with a small sample of female college students with MD suggests that combining HRV biofeedback with psychotherapy reduces not only depressive symptoms but also increases HRV (Caldwell and Steffen, 2018). Therefore, from a translational perspective, future studies should examine (i) which kind of interventions improve HRV in MD and (ii) whether a potential increase in HRV reduces risk for CVD or possibly, reduces other biological risk factors for CVD (e.g. inflammation). In this context, it may be of relevance which mechanisms may underlie a potential increase in HRV during psychological treatments. Although speculative, potential mechanisms may include several interrelated factors such as cognitive-affective mechanisms (e.g. mood changes, better cognitive skills to cope with stressors) and behavioral factors (e.g. increased physical activity, relaxation).

This study has important strengths. To determine HRV alterations in MD this set of meta-analyses considered a total of $N = 4220$ subjects. We further conducted separate meta-analyses for specific HRV measures providing a more comprehensive picture for HRV alterations in MD. Finally, we examined the moderating role of study quality, which is *per se* an important contribution to the existing literature. This study also has limitations. A conservative approach was taken in the process of study selection. For example, studies, in which only a very few of the participants did not entirely fulfill our inclusion criteria (e.g. in one study some patients received a low dose of Lorazepam and in another, a low dose of benzodiazepines) were excluded from analyses. On the one hand, this procedure may draw a clear picture of the impact of MD on HRV in the absence of any medication effects. On the other hand, excluding samples with medication may also bias meta-analytic findings in terms of an underestimation of HRV alterations in MD. In addition, our meta-analyses based on cross-sectional studies and do not provide any causal explanation of the relationship between MD and HRV. In this context, it is important to note that we are not able to identify potential mediators between MD and reduced HRV, for example differences between patients and controls in lifestyle factors such as smoking or nutrition.

To conclude, this set of meta-analyses strengthens evidence that MD is associated with alterations in several measures of HRV, a transdiagnostic indicator of stress and cardiovascular health with potential predictive value for poor health outcomes.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291719001351>.

Acknowledgements. This work was supported, in part, by Grant EU 154/2-1 from the German Research Foundation (F.E.).

Author contributions. C.K. and F.E. conceptualized the study and extracted the data. F.E. and C.K. wrote the original draft. All authors reviewed and revised the original draft. C.K. performed statistical analysis. S.S. and M.W. rated the study quality.

Conflict of interest. None.

References

- Bär K-J, Greiner W, Jochum T, Friedrich M, Wagner G and Sauer H (2004) The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. *Journal of Affective Disorders* **82**, 245–252.
- Berger S, Schulz S, Kletta C, Voss A and Bär K-J (2011) Autonomic modulation in healthy first-degree relatives of patients with major depressive disorder. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* **35**, 1723–1728.
- Berger S, Kliem A, Yeragani V and Bär K-J (2012) Cardio-respiratory coupling in untreated patients with major depression. *Journal of Affective Disorders* **139**, 166–171.
- Berntson GG, Lozano DL and Chen Y-J (2005) Filter properties of root mean square successive difference (RMSSD) for heart rate. *Psychophysiology* **42**, 246–252.
- Borenstein M, Hedges LV, Higgins JPT and Rothstein HR (2009) *Introduction to Meta-Analysis*. Chichester: John Wiley & Sons, Ltd.
- Borenstein M, Hedges L, Higgins JPT and Rothstein HR (2014) *Comprehensive meta-analysis version 3*. Computer software. Englewood, NJ: Biostat.
- Brown L, Karmakar C, Grey R, Jindal R, Lim T and Bryant C (2018) Heart rate variability alterations in late life depression: a meta-analysis. *Journal of Affective Disorders* **235**, 456–466.
- Brunoni AR, Kemp AH, Dantas EM, Goulart AC, Nunes MA, Boggio PS, Mill JG, Lotufo PA, Fregni F and Benseñor IM (2013) Heart rate variability is a trait marker of major depressive disorder: evidence from the sertraline vs electric current therapy to treat depression clinical study. *International Journal of Neuropsychopharmacology* **16**, 1937–1949.
- Buccelletti E, Gilardi E, Scaioni E, Galiuto L, Persiani R, Biondi A, Basile F and Silveri NG (2009) Heart rate variability and myocardial infarction: systematic literature review and metaanalysis. *European Review for Medical and Pharmacological Sciences* **13**, 299–307.
- Caldwell YT and Steffen PR (2018) Adding HRV biofeedback to psychotherapy increases heart rate variability and improves the treatment of major depressive disorder. *International Journal of Psychophysiology* **131**, 96–101.
- Carney RM and Freedland KE (2017) Depression and coronary heart disease. *Nature Reviews Cardiology* **14**, 145–155.
- Carney RM, Freedland KE, Stein PK, Skala JA, Hoffman P and Jaffe AS (2005) Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. *Psychosomatic Medicine* **62**, 639–647.
- Chang H-A, Chang C-C, Chen C-L, Kuo TBJ, Lu R-B and Huang S-Y (2012) Major depression is associated with cardiac autonomic dysregulation. *Acta Neuropsychiatrica* **24**, 318–327.
- Chang H-A, Chang C-C, Kuo TBJ and Huang S-Y (2015) Distinguishing bipolar II depression from unipolar major depressive disorder: Differences in heart rate variability. *The World Journal of Biological Psychiatry* **16**, 351–360.
- Chen X, Yang R, Kuang D, Zhang L, Lv R, Huang X, Wu F, Lao G and Ou S (2017) Heart rate variability in patients with major depression disorder during a clinical autonomic test. *Psychiatry Research* **256**, 207–211.

- Christopher P and Murray JL** (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* **388**, 1459–1544.
- Cohen J** (1988) *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ, England: Lawrence Erlbaum Associates.
- Cohen BE, Edmondson D and Kronish IM** (2015) State of the art review: Depression, stress, anxiety, and cardiovascular disease. *American Journal of Hypertension* **28**, 1295–1302.
- Dawood T, Lambert EA, Barton DA, Laude D, Elghozi J-L, Esler MD, Haikerwal D, Kaye DM, Hotchkiss EJ and Lambert GW** (2007) Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. *Hypertension Research* **30**, 285–293.
- Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK and Lancot LK** (2010) A meta-analysis of cytokines in major depression. *Biological Psychiatry* **67**, 446–457.
- Duval S and Tweedie R** (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* **56**, 444–463.
- Elderson L and Whooley MA** (2013) Depression and cardiovascular disease. *Progress in Cardiovascular Diseases* **55**, 511–523.
- Eller NH, Kristiansen J and Hansen ÅM** (2011) Long-term effects of psychosocial factors of home and work on biomarkers of stress. *International Journal of Psychophysiology* **79**, 195–202.
- Euteneuer F and Rief F** (2016) Psychotherapy and Cardiovascular Risk Factors in Depression. Available at <http://clinicaltrials.gov/ct2/show/NCT02787148> (Identification No. NCT02787148).
- Euteneuer F, Mills PJ, Rief W, Ziegler MG and Dimsdale JE** (2012) Association of in vivo β -adrenergic receptor sensitivity with inflammatory markers in healthy subjects. *Psychosomatic Medicine* **74**, 271–277.
- Gan Y, Gong Y, Tong X, Sun H, Cong Y, Dong X, Wang Y, Xu X, Yin X, Deng J, Li L, Cao S and Lu Z** (2014) Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. *BMC Psychiatry* **14**, 1–11.
- Gidron Y, Deschepper R, De Couck M, Thayer JF and Velkeniers B** (2018) The vagus nerve can predict and possibly modulate non-communicable chronic diseases: introducing a neuroimmunological paradigm to public health. *Journal of Clinical Medicine* **7**, E371.
- Goldston K and Baillie AJ** (2008) Depression and coronary heart disease: a review of the epidemiological evidence, explanatory mechanisms and management approaches. *Clinical Psychology Review* **28**, 288–306.
- Haarala A, Kähönen M, Eklund C, Jylhävä J, Koskinen T, Taittonen L, Huupponen R, Lehtimäki T, Viikari J, Raitakari OT and Hurme M** (2011) Heart rate variability is independently associated with C-reactive protein but not with serum amyloid A. The cardiovascular risk in young Finns study. *European Journal of Clinical Investigation* **41**, 951–957.
- Hackett ML and Pickles K** (2014) Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. *International Journal of Stroke* **9**, 1017–1025.
- Halaris A** (2016) Inflammation-associated co-morbidity between depression and cardiovascular disease. In Dantzer R and Capuron L (eds), *Current Topics in Behavioral Neurosciences*, vol. **31**. Cham: Springer, pp. 45–70.
- Higgins JPT and Thompson SG** (2002) Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* **21**, 1539–1558.
- Higgins JP and Green S** (2008). *Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series*. *Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series*.
- Higgins JPT and Green S** (2011). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. In *The Cochrane Collaboration*.
- Higgins JPT, Thompson SG, Deeks JJ and Altman DG** (2003) Measuring inconsistency in meta-analyses. *BMJ: British Medical Journal* **327**, 557–560.
- Hillebrand S, Gast KB, de Mutsert R, Swenne CA, Jukema JW, Middeldorp S, Rosendaal FR and Dekkers OM** (2013) Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose–response meta-regression. *EP Europace* **15**, 742–749.
- Howren MB, Lamkin DM and Suls J** (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosomatic Medicine* **71**, 171–186.
- Huang W-L, Liao S-C, Kuo T, Chang L-R, Chen T-T, Chen I-M and Yang C** (2016) The effects of antidepressants and quetiapine on heart rate variability. *Pharmacopsychiatry* **49**, 191–198.
- Jandackova VK, Scholes S, Britton A and Steptoe A** (2016) Are changes in heart rate variability in middle-aged and older people normative or caused by pathological conditions? Findings from a large population-based longitudinal cohort study. *Journal of the American Heart Association* **5**, e002365.
- Jarczok MN, Koenig J, Mauss D, Fischer JE and Thayer JF** (2014) Lower heart rate variability predicts increased level of C-reactive protein 4 years later in healthy, nonsmoking adults. *Journal of Internal Medicine* **276**, 667–671.
- Kemp AH and Quintana DS** (2013) The relationship between mental and physical health: insights from the study of heart rate variability. *Journal of Psychophysiology* **89**, 288–296.
- Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K and Gatt JM** (2010) Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. *Biological Psychiatry* **67**, 1067–1074.
- Kemp AH, Quintana DS and Malhi GS** (2011) Effects of serotonin reuptake inhibitors on heart rate variability: methodological issues, medical comorbidity, and clinical relevance. *Biological Psychiatry* **69**, e25–e26.
- Kemp AH, Quintana DS, Felmingham KL, Matthews S and Jelinek HF** (2012) Depression, comorbid anxiety disorders, and heart rate variability in physically healthy, unmedicated patients: implications for cardiovascular risk. *PLoS ONE* **7**, e30777.
- Kemp AH, Fraguas R, Brunoni AR, Bittencourt MS, Nunes MA, Dantas EM, Andreão RV, Mill JG, Ribeiro ALP, Koenig J, Thayer JF, Benseñor IM and Lotufo PA** (2016) Differential associations of specific selective serotonin reuptake inhibitors with resting-state heart rate and heart rate variability. *Psychosomatic Medicine* **78**, 810–818.
- Kemp AH, Koenig J and Thayer JF** (2017) From psychological moments to mortality: a multidisciplinary synthesis on heart rate variability spanning the continuum of time. *Neuroscience & Biobehavioral Reviews* **83**, 547–567.
- Khandoker AH, Luthra V, Abuallaban Y, Saha S, Ahmed KI, Mostafa R, Chowdhury N and Jelinek HF** (2017) Predicting depressed patients with suicidal ideation from ECG recordings. *Medical & Biological Engineering & Computing* **55**, 793–805.
- Kikuchi M, Hanaoka A, Kidani T, Remijn GB, Minabe Y, Munesue T and Koshino Y** (2009) Heart rate variability in drug-naïve patients with panic disorder and major depressive disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **33**, 1474–1478.
- Koenig J, Kemp AH, Beauchaine TP, Thayer JF and Kaess M** (2016) Depression and resting state heart rate variability in children and adolescents – a systematic review and meta-analysis. *Clinical Psychology Review* **46**, 136–150.
- Kop WJ, Stein PK, Tracy RP, Barzilay JI, Schulz R and Gottdiener JS** (2010) Autonomic nervous system dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression. *Psychosomatic Medicine* **72**, 626–635.
- Kubota Y, Chen LY, Whitsel EA and Folsom AR** (2017) Heart rate variability and lifetime risk of cardiovascular disease: the atherosclerosis risk in communities study. *Annals of Epidemiology* **27**, 619–625, e2.
- Lehofer M, Moser M, Hoehn-Saric R, McLeod D, Liebmann P, Drnovsek B, Egner S, Hildebrandt G and Zapotoczky H-G** (1997) Major depression and cardiac autonomic control. *Biological Psychiatry* **42**, 914–919.
- Licht CMM, de Geus EJC, Zitman FG, Hoogendijk WJG, van Dyck R and Penninx BWJH** (2008) Association between Major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). *Archives of General Psychiatry* **65**, 1358–1367.
- Licht CMM, de Geus EJC, van Dyck R and Penninx BWJH** (2010) Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. *Biological Psychiatry* **68**, 861–868.
- Licht CMM, Penninx BWJH and de Geus EJC** (2011) Reply to: effects of serotonin reuptake inhibitors on heart rate variability: methodological

- issues, medical comorbidity, and clinical relevance. *Biological Psychiatry* **69**, e27–e28.
- Meng L, Chen D, Yang Y, Zheng Y and Hui R** (2012) Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. *Journal of Hypertension* **30**, 842–851.
- Moher D, Liberati A, Tetzlaff J, Altman D and Group P** (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine* **6**, e1000097.
- Nemeroff CB and Goldschmidt-Clermont PJ** (2012) Heartache and heart-break – the link between depression and cardiovascular disease. *Nature Reviews. Cardiology* **9**, 526–539.
- Nicholson A, Kuper H and Hemingway H** (2006a) Depression as an aetiological and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. *European Heart Journal* **27**, 2763–2774.
- Nicholson A, Kuper H and Hemingway H** (2006b) Depression as an aetiological and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. *European Heart Journal* **27**, 2763–2774.
- O'Regan C, Kenny RA, Cronin H, Finucane C and Kearney PM** (2015) Antidepressants strongly influence the relationship between depression and heart rate variability: findings from The Irish longitudinal study on ageing (TILDA). *Psychological Medicine* **45**, 623–636.
- Pieritz K, Süßenbach P, Rief W and Euteneuer F** (2016) Subjective social status and cardiovascular reactivity: an experimental examination. *Frontiers in Psychology* **7**, 1091.
- Rief W, Hennings A, Riemer S and Euteneuer F** (2010) Psychobiological differences between depression and somatization. *Journal of Psychosomatic Research* **68**, 495–502.
- Rohatgi A** (2012) WebPlotDigitalizer: HTML5 based online tool to extract numerical data from plot images. Version 4.1. [WWW document] URL <http://arohatgi.info/WebPlotDigitizer/app/> (accessed on September 2018).
- Rottenberg J** (2007) Cardiac vagal control in depression: a critical analysis. *Biological Psychology* **74**, 200–211.
- Rozanski A, Blumenthal JA, Davidson KW, Saab PG and Kubzansky L** (2005) The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. *Journal of the American College of Cardiology* **45**, 637–651.
- Rugulies R** (2002) Depression as a predictor for coronary heart disease: a review and meta-analysis. *American Journal of Preventive Medicine* **23**, 51–61.
- Schulz S, Koschke M, Bär K-J and Voss A** (2010) The altered complexity of cardiovascular regulation in depressed patients. *Physiological Measurement* **31**, 303–321.
- Schumann A, Andrack C and Bär K-J** (2017) Differences of sympathetic and parasympathetic modulation in major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **79**, 324–331.
- Sgoifo A, Carnevali L, Alfonso M-L and Amore M** (2015) Autonomic dysfunction and heart rate variability in depression. *Stress* **18**, 343–352.
- Shaffer F and Ginsberg JP** (2017) An overview of heart rate variability metrics and norms. *Frontiers in Public Health* **5**, 258.
- Shaffer JA, Whang W, Shimbo D, Burg M, Schwartz JE and Davidson KW** (2012) Do different depression phenotypes have different risks for recurrent coronary heart disease? *Health Psychology Review* **6**, 165–179.
- Shaffer F, McCraty R and Zerr CL** (2014) A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. *Frontiers in Psychology* **5**, 1–19.
- Shinba T** (2014) Altered autonomic activity and reactivity in depression revealed by heart-rate variability measurement during rest and task conditions. *Psychiatry and Clinical Neurosciences* **68**, 225–233.
- Shinba T** (2017) Major depressive disorder and generalized anxiety disorder show different autonomic dysregulations revealed by heart-rate variability analysis in first-onset drug-naïve patients without comorbidity. *Psychiatry and Clinical Neurosciences* **71**, 135–145.
- Tak LM, Riese H, de Bock GH, Manoharan A, Kok IC and Rosmalen JGM** (2009) As good as it gets? A meta-analysis and systematic review of methodological quality of heart rate variability studies in functional somatic disorders. *Biological Psychology* **82**, 101–110.
- Task Force of The European Society of Cardiology and The North American, Society of Pacing and Electrophysiology** (1996) Heart rate variability: standards of measurement, physiological interpretation, and clinical use. *European Heart Journal* **17**, 354–381.
- Taylor CB, Conrad A, Wilhelm FH, Strachowski D, Khaylis A, Neri E, Giese-Davis J, Roth WT, Cooke JP, Kraemer H and Spiegel D** (2009) Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk? *Journal of Psychiatric Research* **43**, 1246–1252.
- Terhardt J, Lederbogen F, Feuerhack A, Hamann-Weber B, Gilles M, Schilling C, Lecci O and Deuschle M** (2013) Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. *Clinical Neuropharmacology* **36**, 198–202.
- Thombs BD, Eric B, Bass M, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE and Ziegelstein Roy C** (2006) Prevalence of Depression in Survivors of Acute Myocardial Infarction. Review of the Evidence. *Journal of General Internal Medicine* **21**, 30–38.
- Udupa K, Sathyaprabha TN, Thirthalli J, Kishore KR, Raju TR and Gangadhar BN** (2007) Modulation of cardiac autonomic functions in patients with major depression treated with repetitive transcranial magnetic stimulation. *Journal of Affective Disorders* **104**, 231–236.
- van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C and Beekman A** (2007) Depression and the risk for cardiovascular diseases: systematic review and meta analysis Koen. *Dialogues in Clinical Neuroscience* **11**, 217–228.
- Voss A, Boettger MK, Schulz S, Gross K and Bär K-J** (2011) Gender-dependent impact of major depression on autonomic cardiovascular modulation. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* **35**, 1131–1138.
- Wittchen H-U, Jacobi F, Klose M and Ryl L** (2010) Gesundheitsberichterstattung des Bundes Heft 51: Depressive Erkrankungen. *Robert Koch Institut; Statistisches Bundesamt* **51**, 3–43.
- World Health Organization** (2008) *The Global Burden of Disease: 2004 Update*. 2004 Update. Geneva, Switzerland: World Health Organization, p. 146.
- World Health Organization** (2017) *Depression and Other Common Mental Disorders: Global Health Estimates*. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. Available online at <http://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?jsessionid=FF5A7B1D7D63B6455DEA1C5E6E7332B9?sequence=1>.
- Wu Q and Kling JM** (2016) Depression and the risk of myocardial infarction and coronary death. *Medicine* **95**, e2815.
- Yeh T-C, Kao L-C, Tzeng N-S, Kuo TBJ, Huang S-Y, Chang C-C and Chang H-A** (2016) Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: findings from the Taiwan Study of Depression and Anxiety (TAISDA). *Progress in Neuro-Psychopharmacology & Biological Psychiatry* **64**, 60–67.
- Yeragani VK, Pohl R, Balon R, Ramesh C, Glitz D, Jung I and Sherwood P** (1991) Heart rate variability in patients with major depression. *Psychiatry Research* **37**, 35–46.
- Yeragani VK, Pohl R, Jampala VC, Balon R, Ramesh C and Srinivasan K** (2000) Increased QT variability in patients with panic disorder and depression. *Psychiatry Research* **93**, 225–235.
- Yeragani VK, Rao KARK, Smitha MR, Pohl RB, Balon R and Srinivasan K** (2002) Diminished chaos of heart rate time series in patients with major depression. *Biological Psychiatry* **51**, 733–744.
- Young HA and Benton D** (2018) Heart-rate variability: a biomarker to study the influence of nutrition on physiological and psychological health? *Behavioural Pharmacology* **29**, 140–151.